Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2 - Management of Special Populations, Patients With Comorbid Conditions, and Risk.

Autor:	Carrascosa JM; Departamento de Dermatología, Hospital Universitari Germans Trias I Pujol, Badalona, Universitat Autònoma de Barcelona, IGTP, Barcelona, España. Electronic address: jmcarrascosac.germanstrias@gencat.cat., Puig L; Departamento de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España., Romero IB; Departamento de Dermatología, Hospital General Universitario de Alicante-ISABIAL- Universidad Miguel Hernández de Elche, Alicante, España., Salgado-Boquete L; Departamento de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, España., Del Alcázar E; Departamento de Dermatología, Hospital Universitari Germans Trias I Pujol, Badalona, Universitat Autònoma de Barcelona, IGTP, Barcelona, España., Lencina JJA; Servicio de Dermatología, Hospital Universitario Vega Baja, Alicante, España., Moreno D; Departamento de Dermatología, Hospital Universitario Virgen Macarena, Universidad de Sevilla, Sevilla, España., de la Cueva P; Servicio de Dermatología, Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid, Madrid, España.
Jazyk:	English; Spanish; Castilian
Zdroj:	Actas dermo-sifiliograficas [Actas Dermosifiliogr] 2022 Jun; Vol. 113 (6), pp. 583-609. Date of Electronic Publication: 2022 Feb 11.
DOI:	10.1016/j.ad.2022.01.024
Abstrakt:	Background and Objectives: Since its inception, the Psoriasis Group (GPs) of the Spanish Academy of Dermatology and Venereology (AEDV) has worked to continuously update recommendations for the treatment of psoriasis based on the best available evidence and incorporating proposals arising from and aimed at clinical practice. An updated GPs consensus document on the treatment of moderate to severe psoriasis was needed because of changes in the treatment paradigm and the approval in recent years of a large number of new biologic agents. Methodology: The consensus document was developed using the nominal group technique complemented by a scoping review. First, a designated coordinator selected a group of GPs members for the panel based on their experience and knowledge of psoriasis. The coordinator defined the objectives and key points for the document and, with the help of a documentalist, conducted a scoping review of articles in Medline, Embase, and the Cochrane Library up to January 2021. The review included systematic reviews and meta-analyses as well as clinical trials not included in those studies and high-quality real-world studies. National and international clinical practice guidelines and consensus documents on the management of moderate to severe psoriasis were also reviewed. The coordinator then drew up a set of proposed recommendations, which were discussed and modified in a nominal group meeting. After several review processes, including external review by other GPs members, the final document was drafted. Results: The present guidelines include updated recommendations on assessing the severity of psoriasis and criteria for the indication of systemic treatment. They also include general principles for the treatment of patients with moderate to severe psoriasis and define treatment goals for these patients as well as criteria for the indication and selection of initial and subsequent therapies Practical issues, such as treatment failure and maintenance of response, are also addressed. (Copyright © 2022 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu